福森藥業(01652.HK)合營江西康德獲授獨家許可進行研產銷多西他賽(環糊精增溶型)注射液
格隆匯 2 月 10日丨福森藥業(01652.HK)宣佈,於2021年2月10日,公司的合營企業江西永豐康德醫藥有限公司("江西康德"()作為被許可方)與獨立第三方比卡生物科技(廣州)有限公司("比卡"()作為許可方)訂立許可協議,據此,(其中包括)江西康德與比卡將就多西他賽(docetaxel)(環糊精(cyclodextrin)增溶型)注射液的研發及商業化進行合作,而江西康德獲授獨家許可(其中包括)於許可地區進行研發活動、生產及銷售多西他賽(環糊精增溶型)注射液。
比卡同意向江西康德授出獨家許可,以(其中包括)於中國進行研發活動、生產及銷售多西他賽(環糊精增溶型)注射液。江西康德將負責多西他賽(環糊精增溶型)注射液的後續臨牀研究、藥品註冊、市場營銷及推廣,其將於許可地區獲授予有關多西他賽(環糊精增溶型)注射液所有適應症的商業化權利。江西康德與比卡將共同監督及協調多西他賽(環糊精增溶型)注射液的研發,並繼續推進取得中國國家藥品監督管理局頒發的藥品註冊批准。根據許可協議,江西康德須(i)於籤立許可協議後向比卡支付預付款項;(ii)視乎多西他賽(環糊精增溶型)注射液研發階段,向比卡支付里程碑付款;及(iii)就銷售多西他賽(環糊精增溶型)注射液向比卡支付許可權使用費。
董事會相信,許可協議授權比卡及江西康德加快多西他賽(環糊精增溶型)注射液的商業化。同時,是次合作進一步拓展江西康德在癌症相關療法領域的研發渠道佈局,符合公司中長期創新藥物開發的戰略目標。透過合作,雙方可共同發揮其研發優勢及江西康德於許可地區成熟的商業化營運優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.